Charles Schwab Investment Management »

Inhibikase Therapeutics shares owned by Charles Schwab Investment Management

Quarter-by-quarter ownership of Inhibikase Therapeutics (IKT) shares owned by Charles Schwab Investment Management from 13F filings

Historical chart of Charles Schwab Investment Management investment in Inhibikase Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Inhibikase Therapeutics held by Charles Schwab Investment Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Inhibikase Therapeutics by Charles Schwab Investment Management

Quarter filed Position value Share count Share price at filing
2025-12-31 $312k 152k 2.05
2025-09-30 $247k 152k 1.62
2025-06-30 $297k 152k 1.95